Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis
| Autor: | P. Teal, R. Remick, D. B. Calne, F. R. Peppard, Edwin Mak, S. Calne, E. Ch. Wolters, T. A. Hurwitz |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Psychosis Sedation medicine.medical_treatment Dopamine Agents Dopamine agonist Psychoses Substance-Induced Degenerative disease Double-Blind Method Dibenzazepines medicine Humans Clozapine Confusion Aged Randomized Controlled Trials as Topic Aged 80 and over Psychiatric Status Rating Scales Chemotherapy business.industry Parkinsonism Parkinson Disease Middle Aged medicine.disease Anesthesia Female Neurology (clinical) medicine.symptom business Sleep medicine.drug |
| Zdroj: | Neurology. 40(5) |
| ISSN: | 0028-3878 |
| Popis: | In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine9s usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|